Welcome to our dedicated page for Covalon Technologies news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on Covalon Technologies stock.
Covalon Technologies Ltd. (CVALF) is described in its news releases as an advanced medical technologies and medical device company with expertise in advanced wound care, vascular access, and surgical consumables. The Covalon news flow often combines clinical, commercial, and financial updates, giving investors and healthcare professionals insight into how its technologies are being adopted and how the business is performing.
Recent announcements include detailed financial results, where the company has reported multiple years of revenue growth, profitability, and a debt-free balance sheet, as well as the declaration and payment of its first-ever special cash dividend. These financial updates are accompanied by commentary on revenue by product category and sales channel, including U.S. Vascular Access and Surgical Consumables, U.S. Advanced Wound Care, and International channels.
Covalon’s news also highlights clinical milestones and conference activity. The company has announced a peer-reviewed study in the Journal of the Association for Vascular Access evaluating its VALGuard ae Vascular Access Line Guard in pediatric central line care, with reported reductions in CLABSI rates. It regularly reports on participation in major professional meetings such as the Association for Vascular Access Annual Scientific Meeting, the Association of Pediatric Hematology/Oncology Nurses Conference, and the ANCC National Magnet & Pathway to Excellence Conference, where it showcases VALGuard ae, CovaClear ae, IV Clear ae, and SurgiClear ae dressings.
Investors following CVALF news can expect updates on quarterly and annual financial results, dividend decisions, board and executive changes, new clinical evidence, health economic findings, and Covalon’s presence at investor conferences such as the Planet MicroCap Showcase. This combination of financial, clinical, and market-facing news provides context on how the company positions its technologies and on the evolution of its business across its key sales channels.
Covalon Technologies (OTCQX: CVALF) reported fiscal 2025 results for the year ended Sept 30, 2025, with FY revenue of $32.82M, up 5% year-over-year, and Q4 revenue of $8.69M, the company’s highest quarter of FY25.
The company reported FY net income of $2.06M, adjusted EBITDA of $3.71M, gross margin of 53% (56% excluding inventory write-offs), and recorded $715,983 in inventory provisions. Covalon paid its first-ever special dividend of $0.15 CAD per share, leaving cash of $17.0M and no debt as of Dec 5, 2025. Management named Katie Martinovich as CFO. Key commercial wins included a >50% Q4 increase in U.S. vascular access sales and a >$1M initial purchase order from a new U.S. partner for FY26 Q2 delivery.
Covalon Technologies (OTCQX: CVALF) will release its Q4 and year‑end Fiscal 2025 financial results on Thursday, December 11, 2025 before markets open. A conference call and live webcast to discuss results is scheduled for December 11, 2025 at 8:30 AM ET.
Investors can join the webcast at https://events.q4inc.com/attendee/516259946 or dial North American toll‑free 1‑800‑549‑8228 (Local Toronto 289‑819‑1520, Local New York 646‑564‑2877), Conference ID 57487. A recording and copies of the financial statements and MD&A will be available on www.covalon.com under Investors > News & Events and on SEDAR PLUS.
Covalon Technologies (OTCQX: CVALF) announced payment on November 18, 2025 of its first-ever special cash dividend of C$0.15 per common share, payable to shareholders of record as of November 4, 2025. The dividend follows several quarters of profitability and adoption of Covalon’s proprietary medical technologies.
Key financials cited: revenue +82% to $33.0 million, gross margin up from 41% to 56%, and Adjusted EBITDA flipped from -$7.8M to +$4.1M (trailing twelve months vs FY2022). The company cited its VALGuard clinical evidence study and a new CovaClear indication as growth drivers.
Covalon (OTCQX: CVALF, TSXV: COV) declared its first-ever special cash dividend totaling CAD 4,112,711.55 (CAD 0.15 per common share). The dividend is payable on November 18, 2025 to shareholders of record at the close of business on November 4, 2025. The Special Dividend is designated an eligible dividend for purposes of section 89 of the Income Tax Act (Canada).
The company reported a current cash balance of CAD 18.9 million, no debt, and profitability for the last six quarters. The Board stated it may or may not declare additional special dividends in the future. Shareholders do not need to act to receive the payment and are advised to consult financial advisors about tax treatment.
Covalon (OTCQX: CVALF) announced it will participate in the Planet MicroCap Showcase: TORONTO on October 22, 2025, with CEO Brent Ashton in a fireside chat at 12:30 p.m. ET.
The session will highlight Covalon’s positioning as a microcap medical technologies company — including claims of profitability, a debt-free and cash-rich balance sheet, recent clinical and health-economic evidence supporting its products, and plans to use cash to accelerate shareholder value. The discussion will cover product validation, growth catalysts, and the company’s view on U.S. macro volatility.
Investors can register to attend in person or watch the presentation online; additional company information is available at www.covalon.com and on social media.
Covalon (OTCQX: CVALF) will exhibit at the ANCC National Magnet & Pathway Conference in Atlanta on October 8–10, 2025, where it will showcase products and new clinical evidence aimed at reducing CLABSIs, SSIs, and MARSIs.
Covalon will present peer‑reviewed VALGuard® Line Guard data from Children’s Hospital at Montefiore showing an association with reduced CLABSIs, including a sustained zero‑CLABSI period in a pediatric ICU, and will host authors at its booth #2535. VALGuard is indicated to cover IV connections but is not FDA cleared for infection prevention or CLABSI reduction.
Covalon Technologies (OTCQX: CVALF) announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) 49th Annual Conference from September 25-27, 2025, in Providence, Rhode Island. The company will showcase its vascular access portfolio, highlighting recent clinical evidence and economic findings.
Key achievements include a peer-reviewed study showing 78% reduction in hospital-wide CLABSI rates using VALGuard® Line Guard at Children's Hospital at Montefiore. The company will present its product line including VALGuard® Line Guard, CovaClear® Dressings, IV Clear® Dressings, and SurgiClear®, designed to improve patient outcomes while providing cost savings for hospitals.
Covalon Technologies (OTCQX: CVALF), an advanced medical technologies company, has announced significant leadership changes. Abe Schwartz, the company's largest shareholder and board member since 2008, has been elected as the new Chair of the Board, replacing Amir Boloor, who is stepping down as Executive Chair and director.
Schwartz, who previously served as Board Chair from 2012 to 2020, brings 50 years of experience as a Healthcare and I.T. industry entrepreneur. The company is currently in a strong financial position, being profitable, debt-free, and holding $18 million in cash. Joe Cordiano will continue serving as Lead Independent Director.
Covalon Technologies (OTCQX: CVALF) announced its participation in the Association for Vascular Access (AVA) Annual Scientific Meeting in Orlando from September 18-21, 2025. The company will showcase its vascular access and infection prevention solutions at Booth #515.
A recent peer-reviewed study from the Children's Hospital at Montefiore, published in JAVA, demonstrated that Covalon's VALGuard® Line Guard helped achieve a significant reduction in Central Line-Associated Blood Stream Infections (CLABSIs), including a period of zero CLABSIs in the Pediatric Critical Care Unit.
The company will feature three key products: VALGuard® Line Guard for IV line protection, CovaClear® dressings for IV securement, and IV Clear® dressings with antimicrobial protection, showcasing their integrated approach to infection prevention and line management.
Covalon Technologies (OTCQX: CVALF) announced significant results from a peer-reviewed clinical study of its VALGuard® Vascular Access Line Guard published in the Journal of the Association for Vascular Access. The study, conducted at the Children's Hospital at Montefiore, demonstrated remarkable effectiveness in reducing central line-associated bloodstream infections (CLABSIs).
The study revealed a 100% decrease in CLABSI rates in the Pediatric Critical Care Unit (PCCU), dropping from 1.8 CLABSIs per 1,000 line days to 0.0 over 16 months post-implementation. The Acute Care Units saw a 53% reduction in CLABSI rates, decreasing from 1.5 to 0.7 CLABSIs per 1,000 line days.
FAQ
What is the current stock price of Covalon Technologies (CVALF)?
What is the market cap of Covalon Technologies (CVALF)?
